Skip to main content
ZBIO
NASDAQ Life Sciences

Director Lu Hongbo Buys $1.5M in Zenas BioPharma Public Offering, Signaling Confidence

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$21.9
Mkt Cap
$1.121B
52W Low
$6.11
52W High
$44.6
52W Position info
258% above low
Off High info
51% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

ZBIO has more than doubled off its 52-week low of $6.11 on elevated volume (2.6× avg).

Summary

Director Lu Hongbo purchased $1.5 million worth of Zenas BioPharma common stock at the offering price of $20.00 per share, participating in the company's recent public offering.


Key Events · Ownership and Investor Activity · ZBIO

  • Director Participates in Public Offering

    Director Lu Hongbo acquired 75,000 shares of common stock for $1,500,000 at a price of $20.00 per share, as part of the company's recent underwritten public offering.

  • Vote of Confidence

    The purchase signals strong insider confidence, especially given the recent dilutive public offering and the stock's prior reaction to the pricing.

  • Part of Broader Accumulation

    This transaction adds to a net accumulation of over $2.1 million in open market purchases by insiders over the last 90 days.


Analysis · ZBIO · Life Sciences

This significant purchase by Director Lu Hongbo, totaling $1.5 million, demonstrates a strong vote of confidence in Zenas BioPharma, particularly as it occurred within the recently completed public offering. The company recently raised $300 million through concurrent offerings of common stock and convertible senior notes, which typically causes dilution and can pressure the stock price. An insider's decision to invest a substantial amount at the offering price, especially after the stock experienced a significant drop following the offering announcement, suggests a belief in the company's long-term prospects and the strategic use of the raised capital. This purchase contributes to a pattern of insider accumulation observed over the last 90 days.

At the time of this filing, ZBIO was trading at $21.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.11 to $44.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZBIO - Latest Insights

ZBIO
Jun 02, 2026, 7:06 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $17.38
Real-time Price: $32.80 info
Change: +$15.42 (+89%) info
Market Cap: $2.039B info
ZBIO
May 13, 2026, 6:53 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $19.16
Real-time Price: $32.80 info
Change: +$13.64 (+71%) info
Market Cap: $2.039B info
ZBIO
May 13, 2026, 6:36 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $19.16
Real-time Price: $32.80 info
Change: +$13.64 (+71%) info
Market Cap: $2.039B info
ZBIO
May 13, 2026, 6:14 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $19.16
Real-time Price: $32.80 info
Change: +$13.64 (+71%) info
Market Cap: $2.039B info
ZBIO
May 05, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $20.76
Real-time Price: $32.80 info
Change: +$12.04 (+58%) info
Market Cap: $2.039B info